摘要
目的探讨急性心肌梗死(AMI)患者经皮冠状动脉介入(PCI)术后血清磷酸肌醇3-激酶C2A(PIK3C2A)mRNA表达及与预后的关系。方法选取2016年5月至2018年6月北京市昌平区医院收治的187例接受PCI治疗的AMI患者作为研究对象。采用RT-qPCR法检测AMI患者血清PIK3C2A mRNA相对表达,并分析其与预后的关系。结果AMI患者PCI术后6个月共有22例(11.76%)发生预后不良。PCI术后预后不良组患者血清PIK3C2A mRNA相对表达量低于预后良好组(t=4.567,P<0.05)。PCI术后血清PIK3C2A mRNA评估AMI患者预后的AUC为0.845。Logistic多因素回归分析显示NYHA分级、冠状动脉病变支数、AMI至血管开通时间及PIK3C2A mRNA与心肌梗死患者PCI术后预后不良密切相关[OR(95%CI)=4.312(1.258~7.726)、4.109(1.022~7.307)、5.528(1.746~11.042)、4.857(1.437~9.113),P<0.05]。结论AMI患者PCI术后血清PIK3C2A mRNA相对表达与患者预后不良密切相关,检测血清PIK3C2A mRNA相对表达有助于评估患者预后。
Objective To investigate the expression of serum phosphoinositol 3-kinase C2A(PIK3C2A)in patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI)and its relationship with prognosis.Methods 187 AMI patients who received PCI treatment in Beijing Changping district hospital from May 2016 to June 2018 were selected as the research objects.The relative expression of PIK3C2A mRNA in serum of patients with AMI was detected by RT-q PCR,and the relationship between PI3Ks and prognosis was analyzed.Results A total of 22 patients(11.76%)with AMI had poor prognosis 6 months after PCI.The relative expression of PIK3C2A mRNA in patients with poor prognosis after PCI was lower than that in patients with good prognosis(t=4.567,P<0.05).The AUC of serum PIK3C2A mRNA evaluating prognosis of AMI after PCI was 0.845.Logistic multivariate regression analysis showed that NYHA classification,number of coronary lesion branches,time from AMI to vascular opening and PIK3C2A mRNA were closely related to poor prognosis of patients with AMI after PCI[OR(95%CI)=4.312(1.258-7.726),4.109(1.022-7.307),5.528(1.746-11.042),4.857(1.437-9.113);P<0.05].Conclusion The relative expression of PIK3C2A mRNA in serum after PCI in patients with AMI is closely related to poor prognosis.Detecting the relative expression of PIK3C2A mRNA in serum is helpful to evaluate the prognosis of patients with AMI.
作者
向南坡
吴铮
Xiang Nanpo;Wu Zheng(Department of Cardiology,Beijing Changping District Hospital,Beijing 102200,China;Department of Cardiology,Beijing Anzhen Hospital Affiliated to the Capital University of Medical Sciences,Beijing 100029,China)
出处
《心脑血管病防治》
2021年第5期469-471,487,共4页
CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT